9/9/2013

ThromboGenics and Bicycle Therapeutics agreed to collaborate in the development of treatments for diabetic macular edema and other eye conditions using the latter's bicyclic peptides. The deal entitles Bicycle to an upfront payment, milestone fees and sales royalties.

Full Story:
PharmaTimes (U.K.)

Related Summaries